Fundraise / allotmentFiled on BSE ·
Anupam Rasayan India Ltd acquires 2,60,065 shares in Tanfac Industries Limited
Anupam Rasayan · Chemicals & Petrochemicals
What the filing says
- Acquired 2,60,065 equity shares (0.73% of paid-up capital) of Tanfac at Rs. 2,341/share for Rs. 60.88 crore
- Tanfac Industries Ltd is a fluorine chemistry company with FY 2025-26 turnover of ₹711.10 crore, incorporated in 1972
- Acquisition approved on September 7, 2026; completion expected by September 9, 2026, via preferential issue
Original filing
Announcement under Regulation 30 (LODR)-Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue: Rank 1Margin: Rank 1
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Anupam Rasayan
- Acquisition / mergerAnupam Rasayan completes acquisition of 48.2% stake in Bliss GVS Pharma
- Acquisition / mergerAnupam Rasayan India acquires 2.12% stake in Bliss GVS Pharma on Sept 28, 2026
- Board / shareholder meeting outcomeAnupam Rasayan India Ltd approves 23rd AGM, dividend record date, share acquisition
Other fundraise / allotment filings this fortnight
- Fundraise / allotmentInox GreenInox Green Energy Services Ltd allotted 1.81 crore equity shares via QIP in Sept 2026
- Fundraise / allotmentInox GreenInox Green Energy Services completes Qualified Institutions Placement on Sept 29, 2026
- Fundraise / allotmentBharat Parenterals LtdBharat Parenterals Limited approves preferential allotment of 9.13 lakh equity shares
- Fundraise / allotmentAurum Proptech LtdAurum PropTech allots 1.98 crore equity shares to REA India on preferential basis
- Fundraise / allotmentAurum Proptech LtdAurum PropTech Limited allots 1.98 crore shares to REA India on preferential basis
- Fundraise / allotmentRepco Home FinRepco Home Finance approved raising ₹1500 Cr NCDs and ₹1000 Cr Commercial Paper
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.